The value of screening HIV-infected individuals for didanosine-related liver disease?

Antivir Ther. 2011;16(6):941-2. doi: 10.3851/IMP1875.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / adverse effects*
  • Didanosine / adverse effects*
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Liver Diseases / diagnosis*
  • Liver Diseases / etiology*
  • Mass Screening*

Substances

  • Anti-HIV Agents
  • Didanosine